[Genetic testing in patients with cancer; new developments]

Area of Science:

• Oncology
• Medical Genetics
• Personalized Medicine

Background:

• Approximately 5% of cancer patients harbor a causative germline mutation.
• Germline mutations have significant implications for patient treatment, follow-up, and cascade screening of at-risk relatives.
• Tumor DNA testing is increasingly used to identify actionable targets for personalized cancer therapy.

Purpose of the Study:

• To discuss the implications of germline and tumor DNA testing in cancer patients.
• To highlight the trend towards mainstreaming genetic testing in clinical practice.
• To emphasize the need for physician awareness and collaboration in genetic testing.

Main Methods:

• Review of current developments in cancer genetic testing.
• Discussion of the impact of genetic testing on patient management and family members.
• Analysis of the trend towards integrating genetic testing into routine clinical practice.

Main Results:

• Germline mutations in 5% of cancer patients necessitate careful consideration for treatment and family screening.
• Tumor testing aids in identifying personalized treatment strategies.
• The mainstreaming of genetic testing requires enhanced physician education and interdisciplinary collaboration.

Conclusions:

• Genetic testing, encompassing both germline and tumor analysis, is crucial for tailored cancer treatment and prevention.
• Treating physicians must be equipped to manage the implications of genetic testing.
• Effective collaboration between clinical genetics and treating physicians ensures optimal patient care and family risk assessment.